Embla Medical hfOSSFF 92 PS Ratio is 1.83 as of Jun. 25, 2026, which is 44% below its 10-year median of 3.29. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Embla Medical hf ranks better than 63.93% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Embla Medical hf's share price is $4.15.
Embla Medical hf's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.26. Hence, Embla Medical hf's PS Ratio for today is 1.83.
Good Sign:
Embla Medical hf stock PS Ratio (=1.79) is close to 10-year low of 1.79.
The historical rank and industry rank for Embla Medical hf's PS Ratio or its related term are showing as below:
OSSFF'
s PS Ratio Range Over the Past 10 Years
Min: 1.79 Med: 3.29 Max: 5.17
Current: 1.79
During the past 13 years, Embla Medical hf's highest PS Ratio was 5.17. The lowest was 1.79. And the median was 3.29.
OSSFF's PS Ratio is ranked better than 63.93% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.865
vs OSSFF: 1.79
Embla Medical hf revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Embla Medical hf was 3.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.70% per year.
During the past 13 years, Embla Medical hf's highest 3-Year average Revenue per Share Growth Rate was 27.90% per year. The lowest was 0.40% per year. And the median was 8.50% per year.
Back to Basics: PS Ratio
Embla Medical hf (OTCPK:OSSFF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Embla Medical hf PS Ratio Related Terms
Embla Medical hf PS Ratio Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's PS Ratio distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Embla Medical hf's Share Price of today is $4.15. Embla Medical hf's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Embla Medical hf (OSSFF) has a PS Ratio of 1.83 as of Jun. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Embla Medical hf and its competitors. This is 44% below median its historical median of 3.29. Over the past decade, Embla Medical hf's PS Ratio has ranged from 1.79 to 5.17. According to the industry distribution chart, Embla Medical hf ranks #290 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 36.1%.
Is Embla Medical hf's PS Ratio too high?
Embla Medical hf's current PS Ratio of 1.83 is 44% below median its 10-year median of 3.29. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 5.17. The Medical Devices & Instruments industry median PS Ratio is 2.87. Embla Medical hf's value of 1.83 is 36.1% below this industry median. Based on the distribution chart, Embla Medical hf ranks #290 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #290 out of 804 companies for PS Ratio. This puts Embla Medical hf in the upper half of its industry. The industry median PS Ratio is 2.87. Embla Medical hf's value of 1.83 is 36.1% below this benchmark. Historically, Embla Medical hf's own PS Ratio has ranged from 1.79 to 5.17 over the past decade. While the company's 10-year median is 3.29 vs. the industry median of 2.87, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current PS Ratio of 1.83 is 36.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current PS Ratio is 1.83, which is 44% below median its own 10-year median of 3.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current PS Ratio of 1.83. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current PS Ratio is 1.83, which is 44% below median its 10-year median of 3.29 and 36.1% below the Medical Devices & Instruments industry median of 2.87. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current PS Ratio is 1.83 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.
Key valuation signals for OSSFF:
PS Ratio: 1.83 (44% below median its 10-year median of 3.29)
GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
Industry Position: 36.1% below the Medical Devices & Instruments median (#290 of 804)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
